Skip to main content

Table 4 Trials of bevacizumab in early-stage breast cancer: adjuvant therapy

From: Antiangiogenic therapy for breast cancer

Reference Phase Number of patients Treatment Clinical CHF LVEF <40% DFS
Miller et al. [40] II (two-arm non-randomised) 104 B1 + (ddAC → paclitaxel) 2 4 NR
   122 (HER2 status not reported) ddAC → B + paclitaxel 2 1 NR
Hart et al. [41] IIb (randomised) 59 HER2-negative randomised: B2 + AC → T 1 NR NR
   61 B2 + ACT 2 NR NR
   39 HER2-positive: B2 + TCH 0 NR NR
Mayer et al. [42] II 40 B2 +/- trastuzumab +/- endocrine therapy 0 0 NR
McArthur et al. [112] II 76 B2 + ddAC × 4 → nab-paclitaxel × 4 0 0 NR
  1. AC, doxorubicin + cyclophosphamide; ACT, doxorubicin + cyclophosphamide + docetaxel; B1, bevacizumab 10 mg/kg every second weeks × 26; B2, bevacizumab15 mg/kg every 3 weeks for a total of 52 weeks; CHF, congestive heart failure; ddAC, dose dense doxorubicin + cyclophosphamide; DFS, diseas-free survival; LVEF, left vntricular ejection fraction; NR, not reported; T, docetaxel; TCH, docetaxel + carboplatin + trastuzumab.